Dr. Antonoff completed her undergraduate studies at the University of Pennsylvania and earned her medical degree at the University of Minnesota, where she also completed internship and residency in General Surgery. Dr. Antonoff completed a fellowship in Cardiothoracic Surgery at Washington University in St Louis. In 2014, she joined MD Anderson, where she's currently an Associate Professor of Thoracic and Cardiovascular Surgery and Program Director for Education. She is the Deputy Head of Education for Surgery.

Dr. Antonoff's research interests include pulmonary metastatic disease, early detection of lung cancer, and local consolidative therapy for stage IV lung cancer. She is the surgical lead for several trials evaluating the role of local consolidative therapy for metastatic non-small cell lung cancer. She holds several leadership roles in the STS, including chair of the STS Council on Member Engagement and its leadership Institute. She serves as the Vice President and President-Elect of the WTS. She further holds leadership roles within the AATS, the STSA, the AWS, IASLC, ESTS, and the TSDA, and Senior Editorial Board positions for Annals of Thoracic Surgery, Journal of Thoracic and Cardiovascular Surgery, Innovations, CTSNet, and Journal of Thoracic Disease.

Dr. Cascone is a Physician-Scientist and Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. She received her medical (summa cum laude) and doctorate degrees from the University of Campania Luigi Vanvitelli in Naples, Italy.

Dr. Cascone completed her postdoctoral studies at MD Anderson Cancer Center where she studied the impact of antiangiogenic therapy on the tumor microenvironment. Following her clinical residency in internal medicine at the Washington University School of Medicine in St. Louis, she joined MD Anderson Cancer Center as a Clinical Fellow in Medical Oncology and later as an Instructor in the Cancer Medicine Advanced Scholar Program. She was then appointed Assistant Professor tenure-track in the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center.

Dr. Cascone leads a basic laboratory and translational research program that focuses on identifying mechanisms of tumor response and resistance to immunotherapy. She also serves as PI on several clinical trials evaluating neoadjuvant and perioperative immunotherapies for patients with operable non-small cell lung cancer, including the NEOSTAR, NeoCOAST, NeoCOAST-2, and CheckMate-77T studies. Her research program is supported by multiple peer-reviewed grants and awards, including NIH/NCI MPI R01 grants and the Lung SPORE award, a Mark Foundation Endeavor award, the Lung Cancer Moon Shot Program and a Sabin Family Foundation Award. She uses information generated from preclinical models and patient-derived samples to identify predictive biomarkers of response and to develop novel therapeutic strategies. Dr. Cascone is a graduate of the MD Anderson Physician Scientist Program and a past recipient of an ASCO Career Development Award and an ASCI Young Physician Scientist Award. She has published widely in leading journals, including Journal of Clinical Investigation, Cell Metabolism, Cancer Discovery, Nature Medicine, and The New England Journal of Medicine.

Dr. Patrick Forde treats patients with lung cancer, mesothelioma, and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins.

Dr. Forde has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies.

Dr. Forde's research examines the role of immunotherapy for mesothelioma and lung cancer and his work has led to the development of several ongoing phase 3 trials. In 2022, his work over several years, published in the New England Journal of Medicine, led to the FDA approval of neoadjuvant chemo-immunotherapy for the treatment of surgically operable lung cancer.

Dr. Salma Jabbour is Professor, Vice Chair of Clinical Research and Faculty Development in Radiation Oncology, and Associate Director of Faculty Affairs and Development at the Rutgers Cancer Institute of New Jersey.

Dr. Jabbour's clinical practice and research focuses on lung cancers and gastrointestinal malignancies and she is the Lead Thoracic and GI Radiation Oncologist. Dr. Jabbour's clinical research resulted in many influential publications in major journals. She has authored over 240 articles and numerous book chapters and monographs.

Dr. Jabbour has served previously as the Senior Editor for the International Journal of Radiation Oncology, Biology and Physics (IJROBP) and Deputy Editor of the IJROBP. She participates in multiple ASTRO committees and was selected as Fellow of ASTRO. She also participates in the Big Ten Cancer Research Consortium Steering Committee and is Chair of the Scientific Review Board at the Rutgers Cancer Institute as well as Leader of the Radiation Oncology Disease Specific Group which she founded.

Dr. Jabbour leads and participates in many pivotal clinical trials involving combinations of systemic therapy and radiation therapy. She is the Principal Investigator of international studies including KeyNote-799 investigating chemoradiation and immunotherapy in Stage 3 lung cancer.

Dr. Jarushka Naidoo is a Professor of Medical Oncology at RCSI University of Health Sciences and a Consultant Medical Oncologist at Beaumont Hospital, specializing in lung cancer, clinical trials and immunotherapy. She trained in Medicine at Trinity College Dublin (graduation: 2006) and completed her internal medicine training through the Royal College of Physicians of Ireland, followed by Higher Specialist Training in medical oncology through the Irish College of High Medical Training via RCPI, in 2012.

Dr. Naidoo completed an awarded advanced medical oncology fellowship at Memorial Sloan Kettering Cancer Centre in New York (US Ranking #1 Cancer Centre worldwide) in Thoracic Oncology and Phase I Immunotherapy under the mentorship of Jedd Wolchok and Naiyer Rizvi from 2013-2015.

After this, she became an Assistant Professor and Attending Physician at Johns Hopkins University in the Thoracic Oncology Division from 2015-2020. During this time, Dr. Naidoo won an NIH K12 Award, IASLC Young Investigator Award, and completed a Masters in Biostatistics and Clinical Investigation from Johns Hopkins University.

In 2020, Dr. Naidoo returned to Ireland and won the Irish Cancer Society's Clinician Research Leader Award in 2021. In 2022, she was promoted to Full Professor of Medical Oncology and is currently the national lung cancer chair for Cancer Trials Ireland and lead the clinical research program focused on lung cancer, at Beaumont Hospital and RCSI University of Health Sciences (Beaumont RCSI Cancer Centre).

Dr. Pompili is an Associate Professor in Psychosocial Oncology and an Honorary Thoracic Surgeon at University Hospital in Hull, UK. She is a Visiting Associate Professor at the University of Leeds.

After completing her general thoracic surgical residency in Italy, Dr. Pompili obtained a PhD from the University of Leeds with a project investigating the Role of Patients Reported Outcomes (PROMS) In Risk Assessment and Treatment Outcomes for Early-Stage NSCLC. Her research focuses on two areas: a) patient-centered and personalized care for thoracic malignancies and b) evidence-based practice in lung cancer surgery with particular interest in risk-stratification and postoperative morbidities.

Dr. Pompili is recognized as a founder of the European Society of Thoracic Surgeons (ESTS) Patient-Centered Working Group leading a European Quality of Life App project for thoracic surgical patients. She is active member of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Group and ISOQOL, working on initiatives to implement PROMs in clinical practice.

She holds national and international leadership roles in the ESTS Women in General Thoracic Surgery Committee, the Society of Thoracic Surgeons, the British Thoracic Oncology Group. She has been recently elected co-chair of the IASLC Diversity and Inclusion Taskforce.

Dr. Sanja Dacic, PhD, is a Professor in the Department of Pathology, as well as the Vice Chair and Director of Anatomic Pathology at Yale School of Medicine.

Dr. Dacic is focused on diagnostic pulmonary and molecular pathology and has been involved in many basic and translational research projects in lung cancer and pleural mesotheliomas that have resulted in numerous peer-reviewed scientific articles, book chapters, and reviews. Dr. Dacic was a member of the Editorial Board for the 5th WHO Classification of Thoracic Tumors. She served as president of the Pulmonary Pathology Society (2019-2022). She is a current chair of the IASLC Pathology Committee (2023-2025).

Dr. Boris Sepesi, MD, FACS is a board-certified surgeon, certified in general surgery and thoracic surgery with extensive expertise and experience in the comprehensive treatment of thoracic and upper gastrointestinal oncological diagnoses, specifically lung cancer, esophageal cancer, gastric cancer, chest wall tumors, tracheal and airway tumors, thymomas, thymic carcinomas, mesothelioma and other thoracic oncological diagnoses. His research interests include immunotherapy, targeted therapy, chemotherapy and clinical trials, as well as team building and multi-disciplinary care of complex thoracic oncology patients.

Dr. Henning Willers, FASTRO, is the Director of the Thoracic Radiation Oncology Service at Massachusetts General Hospital (MGH) and he also directs the Radiation Biology & Research Program. He obtained his M.D. from the University of Hamburg Medical School in Germany in 1994. After two years of residency training in radiation oncology in Germany, he came to Boston to work as a research fellow on DNA repair in the laboratory of Simon Powell, MD, PhD and completed his residency training in radiation oncology at the MGH in 2005.

As a clinician-scientist, Dr. Willers has a busy clinical practice focusing on the care of patient with thoracic cancers of various types while focusing on novel therapies for KRAS-mutant and EGFR-mutant lung cancer in the laboratory. Dr. Willers has also uncovered biological properties of proton radiation that potentially can be therapeutically exploited. He has dedicated his career to radiation biology research and education and is currently serving as the Biology Section Editor for the Red Journal. His overarching goal is to advance precision radiation medicine that combines the latest in biological therapies with high-precision radiation therapy to increase the likelihood of cure without complications for patients with lung cancer